vs
Side-by-side financial comparison of AdvanSix Inc. (ASIX) and CORVEL CORP (CRVL). Click either name above to swap in a different company.
AdvanSix Inc. is the larger business by last-quarter revenue ($359.9M vs $235.6M, roughly 1.5× CORVEL CORP). CORVEL CORP runs the higher net margin — 10.3% vs -0.8%, a 11.0% gap on every dollar of revenue. On growth, AdvanSix Inc. posted the faster year-over-year revenue change (9.4% vs 3.4%). AdvanSix Inc. produced more free cash flow last quarter ($36.1M vs $35.2M). Over the past eight quarters, CORVEL CORP's revenue compounded faster (6.6% CAGR vs 3.4%).
AdvanSix Inc. is an American chemical company that produces nylon 6 and related chemicals such as caprolactam and ammonium sulfate fertilizers. It operated as Honeywell's Resins and Chemicals division until 2016, when it was spun off as a separate company. The unit accounted for 3 percent of Honeywell's sales at the time. For 2019, revenue is estimated at $1.4 billion. The company traces its lineage to the H. W. Jayne Company, established 1884 in Frankford, Pennsylvania.
Corvel Corp is a U.S.-headquartered provider of integrated workers’ compensation, healthcare management, and risk mitigation solutions. It serves insurance carriers, self-insured employers, and public sector clients, delivering services to control healthcare costs, improve care outcomes, and optimize administrative operations.
ASIX vs CRVL — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $359.9M | $235.6M |
| Net Profit | $-2.8M | $24.2M |
| Gross Margin | 7.6% | 23.3% |
| Operating Margin | -0.7% | 13.7% |
| Net Margin | -0.8% | 10.3% |
| Revenue YoY | 9.4% | 3.4% |
| Net Profit YoY | -892.9% | 1.7% |
| EPS (diluted) | $-0.11 | $0.47 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $359.9M | $235.6M | ||
| Q3 25 | $374.5M | $239.6M | ||
| Q2 25 | $410.0M | $234.7M | ||
| Q1 25 | $377.8M | $231.5M | ||
| Q4 24 | $329.1M | $228.0M | ||
| Q3 24 | $398.2M | $224.4M | ||
| Q2 24 | $453.5M | $211.7M | ||
| Q1 24 | $336.8M | $207.2M |
| Q4 25 | $-2.8M | $24.2M | ||
| Q3 25 | $-2.6M | $27.9M | ||
| Q2 25 | $31.4M | $27.2M | ||
| Q1 25 | $23.3M | $26.4M | ||
| Q4 24 | $352.0K | $23.8M | ||
| Q3 24 | $22.3M | $23.4M | ||
| Q2 24 | $38.9M | $21.6M | ||
| Q1 24 | $-17.4M | $19.5M |
| Q4 25 | 7.6% | 23.3% | ||
| Q3 25 | 6.8% | 24.3% | ||
| Q2 25 | 14.3% | 24.2% | ||
| Q1 25 | 14.2% | 25.0% | ||
| Q4 24 | 3.4% | 23.2% | ||
| Q3 24 | 14.4% | 22.6% | ||
| Q2 24 | 17.9% | 22.7% | ||
| Q1 24 | 0.9% | 20.9% |
| Q4 25 | -0.7% | 13.7% | ||
| Q3 25 | -0.9% | 15.0% | ||
| Q2 25 | 7.7% | 15.0% | ||
| Q1 25 | 7.7% | 14.4% | ||
| Q4 24 | -3.9% | 13.5% | ||
| Q3 24 | 7.5% | 12.8% | ||
| Q2 24 | 11.5% | 13.2% | ||
| Q1 24 | -7.0% | 10.9% |
| Q4 25 | -0.8% | 10.3% | ||
| Q3 25 | -0.7% | 11.6% | ||
| Q2 25 | 7.7% | 11.6% | ||
| Q1 25 | 6.2% | 11.4% | ||
| Q4 24 | 0.1% | 10.4% | ||
| Q3 24 | 5.6% | 10.4% | ||
| Q2 24 | 8.6% | 10.2% | ||
| Q1 24 | -5.2% | 9.4% |
| Q4 25 | $-0.11 | $0.47 | ||
| Q3 25 | $-0.10 | $0.54 | ||
| Q2 25 | $1.15 | $0.52 | ||
| Q1 25 | $0.86 | $-1.23 | ||
| Q4 24 | $0.02 | $0.46 | ||
| Q3 24 | $0.82 | $1.35 | ||
| Q2 24 | $1.43 | $1.25 | ||
| Q1 24 | $-0.65 | $1.12 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $19.8M | $230.0M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $815.2M | $375.7M |
| Total Assets | $1.7B | $644.8M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $19.8M | $230.0M | ||
| Q3 25 | $23.7M | $207.5M | ||
| Q2 25 | $18.4M | $202.0M | ||
| Q1 25 | $8.3M | $170.6M | ||
| Q4 24 | $19.6M | $162.9M | ||
| Q3 24 | $17.3M | $138.3M | ||
| Q2 24 | $12.1M | $131.9M | ||
| Q1 24 | $20.6M | $105.6M |
| Q4 25 | $815.2M | $375.7M | ||
| Q3 25 | $818.2M | $362.8M | ||
| Q2 25 | $823.7M | $342.5M | ||
| Q1 25 | $794.4M | $322.0M | ||
| Q4 24 | $774.6M | $300.9M | ||
| Q3 24 | $766.4M | $282.8M | ||
| Q2 24 | $746.6M | $263.9M | ||
| Q1 24 | $713.2M | $247.6M |
| Q4 25 | $1.7B | $644.8M | ||
| Q3 25 | $1.7B | $611.7M | ||
| Q2 25 | $1.6B | $597.4M | ||
| Q1 25 | $1.6B | $546.0M | ||
| Q4 24 | $1.6B | $538.8M | ||
| Q3 24 | $1.5B | $518.6M | ||
| Q2 24 | $1.5B | $486.2M | ||
| Q1 24 | $1.5B | $454.7M |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $63.7M | $46.1M |
| Free Cash FlowOCF − Capex | $36.1M | $35.2M |
| FCF MarginFCF / Revenue | 10.0% | 14.9% |
| Capex IntensityCapex / Revenue | 7.7% | 4.7% |
| Cash ConversionOCF / Net Profit | — | 1.91× |
| TTM Free Cash FlowTrailing 4 quarters | $6.4M | $104.3M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $63.7M | $46.1M | ||
| Q3 25 | $26.6M | $25.0M | ||
| Q2 25 | $21.1M | $55.0M | ||
| Q1 25 | $11.4M | $22.9M | ||
| Q4 24 | $64.2M | $41.6M | ||
| Q3 24 | $57.3M | $22.3M | ||
| Q2 24 | $50.2M | $40.4M | ||
| Q1 24 | $-36.2M | $15.2M |
| Q4 25 | $36.1M | $35.2M | ||
| Q3 25 | $66.0K | $15.3M | ||
| Q2 25 | $-7.2M | $39.5M | ||
| Q1 25 | $-22.6M | $14.3M | ||
| Q4 24 | $29.8M | $32.1M | ||
| Q3 24 | $26.8M | $12.4M | ||
| Q2 24 | $16.7M | $32.8M | ||
| Q1 24 | $-71.6M | $5.2M |
| Q4 25 | 10.0% | 14.9% | ||
| Q3 25 | 0.0% | 6.4% | ||
| Q2 25 | -1.7% | 16.8% | ||
| Q1 25 | -6.0% | 6.2% | ||
| Q4 24 | 9.1% | 14.1% | ||
| Q3 24 | 6.7% | 5.5% | ||
| Q2 24 | 3.7% | 15.5% | ||
| Q1 24 | -21.3% | 2.5% |
| Q4 25 | 7.7% | 4.7% | ||
| Q3 25 | 7.1% | 4.1% | ||
| Q2 25 | 6.9% | 6.6% | ||
| Q1 25 | 9.0% | 3.7% | ||
| Q4 24 | 10.4% | 4.2% | ||
| Q3 24 | 7.7% | 4.4% | ||
| Q2 24 | 7.4% | 3.6% | ||
| Q1 24 | 10.5% | 4.8% |
| Q4 25 | — | 1.91× | ||
| Q3 25 | — | 0.90× | ||
| Q2 25 | 0.67× | 2.02× | ||
| Q1 25 | 0.49× | 0.87× | ||
| Q4 24 | 182.29× | 1.75× | ||
| Q3 24 | 2.57× | 0.95× | ||
| Q2 24 | 1.29× | 1.87× | ||
| Q1 24 | — | 0.78× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
ASIX
| Plant Nutrients | $140.0M | 39% |
| Chemical Intermediates | $92.8M | 26% |
| Caprolactam | $64.4M | 18% |
| Nylon Resins | $62.8M | 17% |
CRVL
| Patient Management Services | $146.1M | 62% |
| Network Solutions Services | $89.6M | 38% |
